However, there was limited clinical evidence comparing their impact on COPD outcomes in patients with type 2 diabetes. Researchers continue studying GLP-1 medications beyond diabetes and weight loss because they may have additional health benefits, such as reducing inflammation, improving lung function, and lowering the risk of conditions like COPD exacerbations, added Avik Ray, MD, MS, research fellow at the Division of Pharmacoepidemiology at Brigham and Womens Hospital and Harvard Medical School, first author of this study
CJC-1295 without DAC (sometimes called modified GRF 1-29) is shorter-acting, producing a more pulse-like release that some providers prefer because it more closely mirrors the body's natural rhythm
You must be receiving treatment in the U.S
But promise without proof is hypothesis, not treatment
The good news is that this fatigue typically improves significantly by week 8 as your body adjusts to the medication